Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple Myeloma

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2489-2500

  Cirstea, Diana ^a   Santo, Loredana ^a   Hideshima, Teru ^a   Eda, Homare ^a   Mishima, Yuko ^a   Nemani, Neeharika ^a   Mahindra, Anuj ^a,c   Yee, Andrew ^a   Gorgun, Gullu ^a   Hu, Yiguo ^a   Ohguchi, Hiroto ^a   Suzuki, Rikio ^a   Cottini, Francesca ^a   Guichard, Sylvie M ^b   Anderson, Kenneth C ^a   Raje, Noopur ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 8055; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MORPHOLINES; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84913556111     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0147     Document Type: Article

References (24)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60.
2. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res 2013;19:3337-44.
3. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
4. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 2011;52:497-500.
5. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2010;285:7866-79.
6. Sankhala K, Giles FJ. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies. Expert Rev Hematol 2009;2: 399-414.
7. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104: 4188-93.
8. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9: 963-75.
9. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41.
10. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, et al. Defi ning the role of TORC1/2 in multiple myeloma. Blood 2011; 118:6860-70.
11. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 2011;6:17-27.
12. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedbackdependent biphasic regulation of AKT signaling. Cancer Discov 2011;1:248-59.
13. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69:1821-7.
14. Oh WJ, Jacinto E.mTORcomplex 2 signaling and functions. Cell Cycle 2011;10:2305-16.
15. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70: 288-98.
16. Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N, et al. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods 2000;235:11-9.
17. Pirkmajer S, Chibalin AV. Serum starvation: caveat emptor. Am J Physiol Cell Physiol 2011;301:C272-9.
18. Qin L, Wang Y, Tao L, Wang Z. AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. J Biochem 2011; 150:151-6.
19. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbo-vic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
20. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40.
21. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856-61.
22. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling inhumanmultiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83.
23. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007;56:343-57.
24. Lacy MQ,Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the antiinsulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008;26: 3196-203.